Acquisition settings for PET of124I administered simultaneously with therapeutic amounts of131I

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1375-1381

  Lubberink, Mark ^a   Van Schie, Annelies ^a   De Jong, Hugo W A M ^a   Van Dongen, Guus A M S ^a   Teule, Gerrit J J ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

124I; Data acquisition; Dosimetry; PET

Indexed keywords

IODINE 124; IODINE 131; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; HUMAN; IMAGE QUALITY; IMAGE RECONSTRUCTION; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY SCANNER; PRIORITY JOURNAL; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; THYROID CANCER; AGED; IMAGE PROCESSING; INSTRUMENTATION; MALE; METHODOLOGY; PHOTON; RADIOMETRY; SCINTISCANNING; THYROID TUMOR; TIME; WHOLE BODY IMAGING;

AGED; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; NEOPLASM METASTASIS; PHANTOMS, IMAGING; PHOTONS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TIME FACTORS; WHOLE BODY IMAGING;

EID: 33749070143     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Flower MA, al Saadi A, Harmer CL, McCready VR, Ott RJ. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med. 1994;21:531-536.
2. Crawford DC, Flower MA, Pratt BE, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med. 1997;24:1470-1478.
3. Erdi YE, Macapinlac H, Larson SM, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging. 1999;2:41-46.
4. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol. 2002;37:169-174.
5. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760-767.
6. Freudenberg LS, Antoch G, Gorges R, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol. 2003;13(suppl 4):L19-L23.
7. 124I-PET/ CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092-2098.
8. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366-1372.
9. Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357-366.
10. Wilson CB, Snook DE, Dhokia B, et al. Quantitative measurement of monoclonal-antibody distribution and blood-flow using positron emission tomography and I-124 in patients with breast-cancer. Int J Cancer. 1991;47:344-347.
11. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023.
12. Daghighian F, Pentlow KS, Larson SM, et al. Development of amethod tomeasure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993;20:402-409.
13. Lundqvist H, Lubberink M, Tolmachev V, et al. Positron emission tomography and radioimmunotargeting: general aspects. Acta Oncol. 1999;38:335-341.
14. 124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912-5919.
15. Verel I, Visser GWM, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655-661.
16. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471-1478.
17. 124Iannexin V and PET. Nucl Med Biol. 2005;32:395-402.
18. Dekker B, Keen H, Lyons S, et al. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol. 2005;32:241-252.
19. Iozzo P, Osman S, Glaser M, et al. In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl Med Biol. 2002;29:73-82.
20. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging. 2004;31:117-128.
21. 124I-iododeoxyuridine in malignant gliomas. J Nucl Med. 2002;43:1444-1451.
22. Herzog H, Tellmann L, Qaim SM, Spellerberg S, Schmid A, Coenen HH. PET quantitation and imaging of the non-pure positron-emitting iodine isotope I-124. Appl Radiat Isot. 2002;56:673-679.
23. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557-1562.
24. 124I. Phys Med Biol. 2004;49:5505-5528.
25. Martin CC, Christian BT, Satter MR, Nickerson LDH, Nickles RJ. Quantitative PET with positron emitters that emit prompt gamma rays. IEEE Trans Med Imaging. 1995;14:681-687.
26. Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative imaging of yttrium-86 with PET: the occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging. 2000;3:85-90.
27. 76Br with 2D and 3D PET. Phys Med Biol. 2002;47:3519-3534.
28. 124I in 2D and 3D PET. IEEE 2004 Nuclear Science Symposium Conference Record. 2004;6:3629-3633.
29. Pentlow KS, Mawlawi O, Daghighian F, Finn RD, Humm JL, Larson SM. Imaging of tracer amounts of I-124 in the presence of therapeutic amounts of I-131 with a standard PET scanner [abstract]. J Nucl Med. 1998;39(suppl):51P.
30. Adam LE, Zaers J, Ostertag H, Trojan H, Bellemann ME, Brix G. Performance evaluation of the whole-body PET scanner ECAT EXACT HR+ following the IEC standard. IEEE Trans Nucl Sci. 1997;44:1172-1179.
31. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med. 1997;38:1614-1623.
32. NEMA Standards Publication NU 2-1994: Performance Measurements of Positron Emission Tomographs. Washington, D.C.: National Electrical Manufacturers Association; 1994.
33. Townsend DW, Choi Y, Sashin D, Mintun MA, Grootoonk S, Bailey DL. An investigation of practical scatter correction techniques for 3D PET [abstract]. J Nucl Med. 1994;35(suppl):50P.
34. Cherry SR, Huang SC. Effects of scatter on model parameter estimates in 3D PET studies of the human brain. IEEE Trans Nucl Sci. 1995;42:1174-1179.
35. Bendriem B, Townsend D. The Theory and Practice of 3D PET. Dordrecht, The Netherlands: Kluwer; 1998.
36. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys. 2003;30:2410-2423.
37. Kull T, Ruckgaber J, Weller R, Reske S, Glatting G. Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode. Cancer Biother Radiopharm. 2004;19:482-490.
38. Tarantola G, Zito F, Gerundini P. PET instrumentation and reconstruction algorithms in whole-body applications. J Nucl Med. 2003;44:756-769.